AZNCF News and Press, AstraZeneca Plc From 09/24/21

The following slide deck was published by AstraZeneca PLC in conjunction with this event. For further details see: AstraZeneca <<AZN>> presents at ESMO 2021Virtual Congress - slideshow

AstraZeneca PLC (AZN) ESMO Investor Science Conference Call September 20, 2021, 03:00 ET Company Participants Chris Sheldon - IR Susan Galbraith - EVP, Oncology Research & Development Sara Hurvitz - Senior Investigator David Fredrickson - Executive Vice-President, Oncology Business Unit S...

John Paulson’s 13F portfolio value remained steady at $4.35B this quarter. Paulson & Company's added DiDi Global & increased Occidental Petroleum while reducing Viatris and dropping Takeda. The top three positions are at 45% of the portfolio. For further detai...

The potential continuation in diabetes and obesity trends may provide positive long-term tailwinds for Novo. With health experts now urging Americans to get tested for diabetes at age 35 vs. 40, a potential increase in diagnoses could create a short-term catalyst. Novo's current d...

The delta variant of SARS-CoV-2 is changing the rules of engagement because it is highly infectious and it gets passed on rapidly. Scientific discoveries help explain why antivirals are ineffective and why nasal treatment looks powerful. Once the virus gets started in a sensitive indi...

The current FDA environment is under heavy scrutiny with much uncertainty. Sesen Bio's lead drug, Vicineum, received a complete response letter from the Agency which put tremendous pressure on the stock. The company is eager to conduct a Type A meeting with the FDA to discuss the ...

A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...

Covid-19's Delta Variant threatens an economic recovery, but may soon turn back. Stocks which fell on fears of a delayed reopening could do well in the coming months. Vaccine manufacturers are overpriced. For further details see: Three Trades To Short The Delta Variant; ...

Regeneron has developed some truly life changing treatment options and has exposure to some undertreated spaces. The stock has run up quite a bit on their stellar performances in the past. The R&D pipeline doesn't look as promising as it did in the past implying that growth ma...

AstraZeneca PLC (AZN) Q2 2021 Earnings Conference Call July 29, 2021 6:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, BioPharmaceuticals Business Unit Marc Dunoyer - Executive Direc...